Interview: Steve Bates – CEO, BioIndustry Association (BIA), UK
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions…
Address: Bristol-Myers Squibb Pharmaceuticals Limited (Uxbridge), MS House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH, United Kingdom
Tel: +44 (0)1895 523000
Since 1858, medicines made by Bristol-Myers Squibb have helped millions of patients around the world fight serious diseases such as cancer, heart disease, diabetes, HIV/AIDS, chronic hepatitis B, rheumatoid arthritis and various psychiatric disorders.
From those early days, the company has been developing our offering to better meet the needs of patients. By combining the best elements of a leading-edge biotech company with the resources of a major pharmaceutical company, BMS is transforming into a new kind of enterprise: a next-generation BioPharma leader.
At the heart of this BioPharma strategy are the medicines that give meaningful hope to patients and physicians and bring value to its shareholders and customers. Since 2002, BMS introduced eight new products for the treatment of numerous serious diseases.
As well as all these products now on the market, scores of additional investigational medicines are advancing through the company’s pharmaceutical development pipeline. In fact, Bristol-Myers Squibb is recognised as having one of the most productive pipelines in the industry.
Over the years, Bristol-Myers Squibb and its employees have received awards and recognition. We have been listed as one of the best companies to work for by The Sunday Times. We have also been acknowledged as an industry leader in environment, health and safety management.
Finally, our philanthropic programmes have given new hope to some of the world’s most vulnerable citizens.
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions…
After a series of recent acquisitions, developing a diverse portfolio comprising four business areas; including OTC and branded prescription medicines, Mylan UK’s country manager, Jean-Yves Brault, takes a step back…
Hugo Fry, managing director of Sanofi UK, details the impact of the company’s changing structure, the continued relevance of the UK market despite the challenges around Brexit, and the significance…
With an appetite to take the next step in its rapid development, EUSA Pharma has already established itself as a leading rare-disease and oncology biotech company in just a short…
Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry (ABPI) reveals his staunch faith in the British health service but calls for the NHS to welcome and…
Liam O’Toole, CEO of Arthritis Research UK, discusses how arthritis impacts the British economy, raising public awareness of the condition, the potential ramifications of Brexit, and the importance of inter-stakeholder…
Mark Hicken, managing director of the UK and Ireland operations of Janssen, the pharmaceutical arm of Johnson & Johnson, highlights the company’s long-standing R&D presence in the UK. He calls…
Sir Robert Lechler, president of the Academy of Medical Sciences (AMS), discusses the Academy’s role in promoting medical research in the UK and how that stands to change in the…
Keith Thompson, CEO of the Cell & Gene Therapy Catapult, one of a number of Catapult institutions in the UK designed to help commercialize innovative research, discusses strategy, funding, international…
Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues, and why Biogen is staying the course with…
Sir John Savill, chief executive of the Medical Research Council between 2010 and 2018, discusses the organization’s transition into part of the new UK Research and Innovation (UKRI) grouping, the…
Steve Ford, CEO of Parkinson’s UK, one of the UK’s leading research-based charities, discusses his organization’s recent Digital Leadership Award, presenting the needs of Parkinson’s patients to stakeholders, and why…
See our Cookie Privacy Policy Here
